Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

被引：0
|
作者：
Jing Wang
Zhi-Yi Zhang
Sharon Lu
Dan Powers
Vikram Kansra
Xiaodong Wang
机构：
[1] TESARO,
[2] Inc.,undefined
来源：
Supportive Care in Cancer | 2019年 / 27卷
关键词：
Rolapitant; Antiemetics; Neurokinin-1 receptor antagonist; Drug interactions; Cytochrome P450;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：819 / 827
页数：8
相关论文
共 50 条
  • [1] Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
    Wang, Jing
    Zhang, Zhi-Yi
    Lu, Sharon
    Powers, Dan
    Kansra, Vikram
    Wang, Xiaodong
    SUPPORTIVE CARE IN CANCER, 2019, 27 (03) : 819 - 827
  • [2] Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population
    Jónrit Halling
    Maria S. Petersen
    Per Damkier
    Flemming Nielsen
    Philippe Grandjean
    Pál Weihe
    Stefan Lundgren
    Mia Sandberg Lundblad
    Kim Brøsen
    European Journal of Clinical Pharmacology, 2005, 61 : 491 - 497
  • [3] Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population
    Halling, J
    Petersen, M
    Damkier, P
    Nielsen, F
    Grandjean, P
    Weihe, P
    Lundgren, S
    Lundblad, M
    Brosen, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 491 - 497
  • [4] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
  • [5] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [6] Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Kirchheiner, J
    Müller, G
    Meineke, I
    Wernecke, KD
    Roots, I
    Brockmöller, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (05) : 459 - 466
  • [7] Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula
    Carano, Francesco
    Sarno, Stefania
    De Fanti, Sara
    Serventi, Patrizia
    Bini, Carla
    Luiselli, Donata
    Pelotti, Susi
    ANNALS OF HUMAN BIOLOGY, 2018, 45 (01) : 66 - 71
  • [8] Effects of H2S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
    Wang, Xianqin
    Han, Anyue
    Wen, Congcong
    Chen, Mengchun
    Chen, Xinxin
    Yang, Xuezhi
    Ma, Jianshe
    Lin, Guanyang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (12): : 24055 - 24063
  • [9] CYP2D6, CYP2C19 AND CYP2C9 GENOTYPING IN A SWEDISH CLINICAL SETTING
    Scordo, M. G.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E9 - E9
  • [10] REVERSIBLE AND TIME-DEPENDENT INHIBITION (TDI) OF CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 AND CYP3A4 IN HUMAN HEPATOCYTE SUSPENSIONS BY MODEL INHIBITORS
    Zhang, J. George
    Thuy Ho
    Patel, Reena
    Trisdale, Sarah K.
    Creegan, Tim
    Stresser, David M.
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S57 - S58
12345